Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Induced Pluripotent Stem Cell (iPSC) Market Revenue Growth On Track For A 9.3% CAGR Through 2030
The induced pluripotent stem cell (ipsc) market has demonstrated significant expansion in recent times. Projections indicate its expansion from $3.67 billion in 2025 to $4.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.5%. Historically, this growth is linked to breakthroughs in cellular reprogramming research, ethical concerns surrounding embryonic stem cells, enhanced funding for stem cell research, an increase in academic research collaborations, and the rising prevalence of chronic and degenerative diseases.
The induced pluripotent stem cell (ipsc) market size is projected to experience substantial growth in the upcoming years, expanding to $5.75 billion by 2030 at a compound annual growth rate (CAGR) of 9.3%. This growth during the forecast period can be attributed to the broadening scope of regenerative medicine applications, a rising demand for personalized therapies, increasing investment in cell and gene therapy, the growing adoption of ipscs in neurological and cardiac research, and favorable regulatory support for advanced therapies. Key trends influencing the forecast period include the expanding use of ipscs in disease modeling, their increasing integration into drug discovery and toxicity testing, the proliferation of patient-specific cell line development, a heightened focus on ethical alternatives to embryonic stem cells, and ongoing advancements in reprogramming efficiency and cell stability.
Get A Free Sample Report With In-Depth Market Insights:
Induced Pluripotent Stem Cell (iPSC) Market Growth Factors: What’s Supporting Expansion?
The escalating occurrence of neurological conditions is expected to propel the growth of the induced pluripotent stem cell market moving forward. A neurological disorder refers to a medical ailment affecting the nervous system, including the brain, spinal cord, and nerves. Common examples include acute spinal cord injury, Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer the potential to study disease mechanisms and facilitate drug testing, thereby providing insights into the causes of neurological disorders and assisting in the development of regenerative therapies for conditions like Parkinson’s and Alzheimer’s disease. For instance, in October 2023, the World Federation of Neurology (WFN), a UK-based international nonprofit neurological organization, reported that over 40% of the global population was living with a neurological condition, and the overall neurological disease burden is projected to nearly double by 2050. Therefore, the increasing prevalence of neurological disorders is driving the growth of the induced pluripotent stem cell market.
Induced Pluripotent Stem Cell (iPSC) Market Segment Breakdown: Which Categories Lead On Revenue?
The induced pluripotent stem cell (ipsc) market covered in this report is segmented –
1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
3) By End-User: Hospitals, Research Laboratories
Subsegments:
1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies
2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research
3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies
4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications
5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research
Induced Pluripotent Stem Cell (iPSC) Market Industry Trends: What’s Reshaping Demand?
Key players in the Induced Pluripotent Stem Cell (iPSC) market are partnering to push iPSC Technology forward, aiming to boost regenerative medicine, refine disease modeling, speed up drug discovery, and create tailored therapeutic options. Induced Pluripotent Stem Cell (iPSC) technology involves scientific methods to revert adult somatic cells (like skin or blood cells) to a pluripotent condition, enabling them to transform into any body cell type. As an example, in April 2024, SCG Cell Therapy Pte Ltd, a biotechnology firm from Singapore, along with the Agency for Science, Technology and Research, a Singaporean statutory board, established joint laboratories focused on progressing cellular immunotherapies. This venture is backed by nearly S$30 million, highlighting Singapore’s dedication to improving biotechnology and healthcare solutions. The partnership seeks to establish scalable production methods for GMP-grade iPSC products, tackling the difficulties of moving lab breakthroughs into practical clinical treatments.
Induced Pluripotent Stem Cell (iPSC) Market Leading Players And Competitive Positioning
Major companies operating in the induced pluripotent stem cell (ipsc) market are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, Parexel, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart
View The Full Induced Pluripotent Stem Cell (iPSC) Market Report:
Induced Pluripotent Stem Cell (iPSC) Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2025. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
